目的：探讨甲磺酸伊马替尼联合大剂量阿糖胞苷治疗复发Ph染色体阳性急性淋巴细胞白血病的疗效。方法：选取2006年10月—2016年1月赣南医学院第一附属医院收治的46例复发Ph阳性急性淋巴细胞白血病患者，按随机数字表法分为对照组和观察组，每组各23例。对照组患者给予常规化疗方案，观察组患者给予甲磺酸伊马替尼联合大剂量阿糖胞苷，比较2组患者的疗效、不良反应发生情况及复发情况。结果：治疗后，观察组患者的总有效率为91．30％（21／23），明显高于对照组的73．91％（17／23），差异有统计学意义（P＜0．05）。对照组患者不良反应发生率为4．34％（1／23），明显低于观察组的21．74％（5／23），差异有统计学意义（P＜0．05）。对照组患者复发率为13．04％（3／23），观察组为4．34％（1／23），2组的差异有统计学意义（P＜0．05）。结论：甲磺酸伊马替尼联合大剂量阿糖胞苷治疗复发Ph染色体阳性急性淋巴细胞白血病有一定临床意义，治疗效果较好，可降低复发率，但临床还应注意相关不良反应的发生。%OBJECTIVE:To probe into the efficacy of imatinib mesylate combined with high-dose cytarabine in treatment of recurrence Ph acute lymphoblastic leukemia . METHODS: 46 patients with recurrence Ph acute lymphoblastic leukemia admitted into the First Affiliated Hospital of Gannan Medical College from Oct .2013 to Jan. 2016 were selected to be divided into observation group and control group via the random number table , with 23 cases in each .The control group were given conventional chemotherapy regimens , and the observation group were treated with imatinib mesylate combined with high-dose cytarabine .The efficacy, incidence of adverse drug reactions and recurrence were compared between two groups .RESULTS:After treatment, the total effective rate of observation group was 91.30%(21/23), significantly higher than that of control group [73.91%(17/23)], with statistically significant difference(P<0.05).The incidence of adverse drug reactions of control group was 4.34%(1/23), significantly lower than that of observation group [ 21.74%( 5/23 ) ] , with statistically significant difference ( P <0.05 ) .The incidence of recurrence in control group was 13.04%( 3/23 ) , and in observation group was 4.34%( 1/23 ) , the difference was statistically significant ( P <0.05 ).CONCLUSIONS: Imatinib mesylate combined with high-dose cytarabine in treatment of recurrence Ph acute lymphoblastic leukemia have a more prominent clinical significance with remarkable treatment effects , which can reduce the incidence of recurrence .However , the clinic still need to attach more importance to the incidence of adverse drug reactions .
展开▼
